Immunic News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.11.25	EQS-News: Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update (EQS Group)
29.10.25	EQS-News: Immunic to Participate in Industry and Investor Conferences in November (EQS Group)
01.10.25	EQS-News: Immunic to Participate in Scientific and Investor Conferences in October (EQS Group)
25.09.25	EQS-News: Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis (EQS Group)
09.09.25	EQS-News: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis (EQS Group)
04.09.25	EQS-News: Immunic to Participate in Investor and Scientific Conferences in September (EQS Group)
07.08.25	EQS-News: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update (EQS Group)
24.06.25	EQS-News: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis (EQS Group)
02.06.25	EQS-News: Immunic to Participate in Investor, Scientific and Industry Conferences in June (EQS Group)
02.05.25	EQS-News: Immunic to Participate in Scientific and Industry Conferences in May (EQS Group)
30.04.25	EQS-News: Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial (EQS Group)
10.04.25	EQS-News: Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments (EQS Group)
09.04.25	EQS-News: Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments (EQS Group)
01.04.25	EQS-News: Immunic, Inc. to Participate in Scientific and Industry Conferences in April (EQS Group)
03.03.25	EQS-News: Immunic to Participate in Scientific and Investor Conferences in March (EQS Group)
26.02.25	EQS-News: Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis (EQS Group)
20.02.25	EQS-News: Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing (EQS Group)
04.02.25	EQS-News: Immunic to Participate in Investor and Scientific Conferences in February (EQS Group)
07.01.25	EQS-News: Immunic Highlights 2024 Accomplishments and Upcoming Milestones (EQS Group)
26.11.24	EQS-News: Immunic, Inc. to Participate in Investor Conference in December (EQS Group)
13.11.24	EQS-News: Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology (EQS Group)
07.11.24	EQS-News: Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update (EQS Group)
31.10.24	EQS-News: Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update (EQS Group)
29.10.24	EQS-News: Immunic to Participate in Industry, Scientific and Investor Conferences in November (EQS Group)
22.10.24	EQS-News: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis (EQS Group)
18.09.24	EQS-News: Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis (EQS Group)
04.09.24	EQS-News: Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome (EQS Group)
28.08.24	EQS-News: Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September (EQS Group)
08.08.24	EQS-News: Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update (EQS Group)
01.08.24	EQS-News: Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update (EQS Group)
24.07.24	EQS-News: Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec (EQS Group)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	102.88	2.45 %	K V
Geberit	624.80	1.96 %	K V
Nestle	80.77	1.94 %	K V
Givaudan	3’307.00	1.85 %	K V
Kuehne+Nagel Int	152.85	1.63 %	K V
Logitech Intl	87.76	-0.43 %	K V
CieFinRichemont	163.25	-1.12 %	K V
Holcim	70.48	-1.59 %	K V
ABB	54.62	-1.83 %	K V
UBS Group	29.77	-1.94 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Immunic Aktie VALOR 47368242 / ISIN US4525EP1011

Nachrichten zu Immunic Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten